MetaCap

Alvotech (ALVO) vs Hemab Therapeutics (COAG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Hemab Therapeutics is the larger company by market cap ($1.84 billion vs $1.47 billion), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALVO+19.08%COAG+15.56%
+83%+26%-32%
May 1, 20261 yearNov 20, 2026
ALVO+19.08%COAG+15.56%
+74%+22%-31%
Apr 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALVO versus COAG key metrics
MetricALVOCOAG
Share price$4.12$39.29
Market cap$1.47B$1.84B
1-day change-3.96%-1.43%
YTD return-19.69%—
1-year return-19.84%—
Forward P/E19.46—
EPS (TTM)$-0.82$-3.55
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$586.32M—
Revenue growth (YoY)+19.74%—
Net income (latest FY)$27.92M—
Gross margin59.82%—
Operating margin13.34%—
Net margin4.76%—
52-week high$6.53$55.42
52-week low$2.94$23.00
Distance from 52-week high-36.91%-29.11%
Analyst consensusbuystrong_buy
Avg. price target upside+82.04%+60.35%
Average volume1.13M495.96K
Shares outstanding356.82M46.73M
Employees1,27959
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Alvotech

ALVO stock →

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,279 employees

About Hemab Therapeutics

COAG stock →

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 59 employees

ALVO vs COAG FAQ

Which is bigger, Alvotech or Hemab Therapeutics?

Hemab Therapeutics (COAG) is larger, with a market capitalization of $1.84B compared with $1.47B for Alvotech (ALVO).

Are Alvotech and Hemab Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons